Format

Send to

Choose Destination
See comment in PubMed Commons below
Cancer Lett. 2005 Aug 26;226(2):95-9. Epub 2004 Dec 16.

Conditionally MYC: insights from novel transgenic models.

Author information

1
Departments of Medicine and Pathology, Division of Oncology, School of Medicine, Stanford University, CCSR 1105B, 269 Campus Drive, Stanford, CA 94305-5151, USA.

Abstract

MYC was one of the first oncogenes identified to be associated with chromosomal aberrations and one of the most common oncogenes involved in the pathogenesis of cancer. However, until recently it was not clear if MYC would be a good target for the treatment of cancer. New conditional transgenic models have been used to demonstrate that even the brief inactivation of MYC can reverse tumorigenesis. Here we review results from recent experimental model systems, which demonstrate that the inactivation of MYC may be a specific and effective treatment for many types of cancer.

PMID:
16039948
DOI:
10.1016/j.canlet.2004.10.043
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center